Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI

by Lee L.S.-U., Seng K.-Y., Wang L.-Z., Yong W.-P., Hee K.-H., Soh T.I., Wong A., Cheong P.F., Soong R., Sapari N.S., Soo R., Fan L., Lee S.-C., Goh B.C.
Published 2018

Pharmacogenetics-Guided Phase i Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

by Soo, R.A, Syn, N, Lee, S.-C, Wang, L, Lim, X.-Y, Loh, M, Tan, S.-H, Zee, Y.-K, Wong, A.L.-A, Chuah, B, Chan, D, Lim, S.-E, Goh, B.-C, Soong, R, Yong, W.-P
Published 2020

PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer

by Mimura K., Teh J.L., Okayama H., Shiraishi K., Kua L.-F., Koh V., Smoot D.T., Ashktorab H., Oike T., Suzuki Y., Fazreen Z., Asuncion B.R., Shabbir A., Yong W.-P., So J., Soong R., Kono K.
Published 2018

Upregulation of plasma C9 protein in gastric cancer patients

by Chong, P.-K., Lee, H., Loh, M.C.S., Choong, L.-Y., Lin, Q., So, J.B.Y., Lim, K.H., Soo, R.A., Yong, W.P., Chan, S.P., Smoot, D.T., Ashktorab, H., Yeoh, K.G., Lim, Y.P.
Published 2014

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

by Toh, H.C., Chen, P.-J., Carr, B.I., Knox, J.J., Gill, S., Ansell, P., McKeegan, E.M., Dowell, B., Pedersen, M., Qin, Q., Qian, J., Scappaticci, F.A., Ricker, J.L., Carlson, D.M., Yong, W.P.
Published 2014

Study protocol: Phase 1 dose escalating study of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis

by Kim, G., Tan, H.L., Chen, E., Teo, S.C., Jang, C.J.M., Ho, J., Ang, Y., Ngoi, N.Y.L., Chee, C.E., Lieske, B., Shabbir, A., Wang, L.-Z., So, J.B.Y., Yong, W.P.
Published 2021

Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer

by Ivanova, T., Zouridis, H., Wu, Y., Cheng, L.L., Tan, I.B., Gopalakrishnan, V., Ooi, C.H., Lee, J., Qin, L., Wu, J., Lee, M., Rha, S.Y., Huang, D., Liem, N., Yeoh, K.G., Yong, W.P., Teh, B.T., Tan, P.
Published 2014

Methylation subtypes and large-scale epigenetic alterations in gastric cancer

by Zouridis, H., Deng, N., Ivanova, T., Zhu, Y., Wong, B., Huang, D., Wu, Y.H., Wu, Y., Tan, I.B., Liem, N., Gopalakrishnan, V., Luo, Q., Wu, J., Lee, M., Yong, W.P., Goh, L.K., Teh, B.T., Rozen, S., Tan, P.
Published 2014

Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer

by Goh, L.K., Liem, N., Vijayaraghavan, A., Chen, G., Lim, P.L., Tay, K.-J., Chang, M., Low, J.S.W., Joshi, A., Huang, H.H., Kalaw, E., Tan, P.H., Hsieh, W.-S., Yong, W.P., Alumkal, J., Sim, H.G.
Published 2014

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1

by Wang, L, Chan, C.E.L, Wong, A.L.-A, Wong, F.C, Lim, S.W, Chinnathambi, A, Alharbi, S.A, Lee, L.S.-U, Soo, R, Yong, W.P, Lee, S.C, Ho, P.C.-L, Sethi, G, Goh, B.C
Published 2020

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

by Subhash, V.V, Yeo, M.S, Wang, L, Tan, S.H, Wong, F.Y, Thuya, W.L, Tan, W.L, Peethala, P.C, Soe, M.Y, Tan, D.S.P, Padmanabhan, N, Baloglu, E, Shacham, S, Tan, P, Koeffler, H.P, Yong, W.P
Published 2020

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

by Ang, Y.L.E., Ho, G.F., Soo, R.A., Sundar, R., Tan, S.H., Yong, W.P., Ow, S.G.W., Lim, J.S.J., Chong, W.Q., Soe, P.P., Tai, B.C., Wang, L., Goh, B.C., Lee, S.-C.
Published 2021

Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous technique

by Heong V., Tay D., Goh S.E., Wee B., Tan T.Z., Soo R., Pang B., Lim D., Gopinathan A., Ow S., Chee C.E., Goh B.C., Lee S.C., Yong W.P., Wong A., Omar M.F.M., Soong R., Tan D.S.P.
Published 2020

CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer

by Roy R.K., Hoppe M.M., Srivastava S., Samanta A., Sharma N., Tan K.T., Yang H., Voon D.C., Pang B., Teh M., Murata-Kamiya N., Hatakeyama M., Chang Y.-T., Yong W.P., Ito Y., Ho K.Y., Tan P., Soong R., Koeffler P.H., Yeoh K.G., Jeyasekharan A.D.
Published 2020

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib

by Wong A.L.A., Lim J.S.J., Sinha A., Gopinathan A., Lim R., Tan C.-S., Soh T., Venkatesh S., Titin C., Sapari N.S., Lee S.-C., Yong W.-P., Tan D.S.P., Pang B., Wang T.-T., Zee Y.-K., Soong R., Trnkova Z., Lathia C., Thiery J.-P., Wilhelm S., Jeffers M., Goh B.-C.
Published 2018

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study

by Heong V., Syn N.L., Lee X.W., Sapari N.S., Koh X.Q., Adam Isa Z.F., Sy Lim J., Lim D., Pang B., Thian Y.L., Ng L.K., Wong A.L., Soo R.A., Yong W.P., Chee C.E., Lee S.-C., Goh B.-C., Soong R., Tan D.S.P.
Published 2020

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

by Deng, N., Goh, L.K., Wang, H., Das, K., Tao, J., Tan, I.B., Zhang, S., Lee, M., Wu, J., Lim, K.H., Lei, Z., Goh, G., Lim, Q.-Y., Tan, A.L.-K., Poh, D.Y.S., Riahi, S., Bell, S., Shi, M.M., Linnartz, R., Zhu, F., Yeoh, K.G., Toh, H.C., Yong, W.P., Cheong, H.C., Rha, S.Y., Boussioutas, A., Grabsch, H., Rozen, S., Tan, P.
Published 2014

Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy

by Tan, I.B., Ivanova, T., Lim, K.H., Ong, C.W., Deng, N., Lee, J., Tan, S.H., Wu, J., Lee, M.H., Ooi, C.H., Rha, S.Y., Wong, W.K., Boussioutas, A., Yeoh, K.G., So, J., Yong, W.P., Tsuburaya, A., Grabsch, H., Toh, H.C., Rozen, S., Cheong, J.H., Noh, S.H., Wan, W.K., Ajani, J.A., Lee, J., Tellez, M.S., Tan, P.
Published 2014

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein

by Thura M., Al-Aidaroos A.Q., Gupta A., Chee C.E., Lee S.C., Hui K.M., Li J., Guan Y.K., Yong W.P., So J., Chng W.J., Ng C.H., Zhou J., Wang L.Z., Yuen J.S.P., Ho H.S.S., Yi S.M., Chiong E., Choo S.P., Ngeow J., Ng M.C.H., Chua C., Yeo E.S.A., Tan I.B.H., Sng J.X.E., Tan N.Y.Z., Thiery J.P., Goh B.C., Zeng Q.
Published 2020